stockportfolio.pro
Telix Pharmaceuticals Limited (TLX)
Healthcare · Biotechnology · NasdaqGS
Telix Pharmaceuticals Limited revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $108.91M | $332.98M | $516.55M | $803.79M |
| Gross profit | $64.58M | $209.53M | $336.16M | $426.44M |
| Net income | $-70.80M | $4.21M | $33.69M | $-7.13M |
| Net margin | -65.0% | 1.3% | 6.5% | -0.9% |
Source: Telix Pharmaceuticals Limited SEC filings (10-K).
Explore 4 years of Telix Pharmaceuticals Limited financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track TLX in your portfolio →
Telix Pharmaceuticals Limited financial history by metric
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Telix Pharmaceuticals Limited — frequently asked questions
What is Telix Pharmaceuticals Limited's revenue?
Telix Pharmaceuticals Limited (TLX) reported revenue of $803.79M for fiscal year 2025, up 55.6% from the prior year, according to its SEC filings.
Is Telix Pharmaceuticals Limited profitable?
No — TLX reported a net loss of $-7.13M in fiscal 2025.
What is TLX's P/E ratio?
Telix Pharmaceuticals Limited trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Telix Pharmaceuticals Limited growing?
TLX's revenue grew at roughly 94.7% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Telix Pharmaceuticals Limited have?
As of fiscal year 2025, TLX carried roughly $405.02M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Telix Pharmaceuticals Limited's gross margin?
TLX's gross margin was 53.1% in fiscal 2025 — gross profit of $426.44M on revenue of $803.79M.
What is Telix Pharmaceuticals Limited's market cap?
Telix Pharmaceuticals Limited (TLX) has a market capitalization of about $3.19B, based on the latest data in our nightly-refreshed cache.
When does Telix Pharmaceuticals Limited's fiscal year end?
TLX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Telix Pharmaceuticals Limited's official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.